Leukemia Clinical Trials and Research | Norton Healthcare Louisville, Ky.

Leukemia Clinical Trials and Research

Norton Cancer Institute is at the forefront of leukemia treatment research. As investigators on numerous trials, our specialist physicians have unparalleled experience with many innovative treatments once they are approved for broad use. Patients also may be eligible to take part in these experimental leukemia treatments. Norton Cancer Institute researchers also contribute to groundbreaking studies and other publications in peer-reviewed journals.

Learn more about participating in a clinical trial at Norton Healthcare.

 

Current Clinical Trials and Studies

Hematological Malignancies

A Phase 1a/1b Dose-Escalation and Expansion Trial of TTI-622 in Patients with Advanced Hematologic Malignancies, Including Lymphoma, Leukemia, and Multiple Myeloma
Study Type: Drug Study
Don Stevens  M.D.
Don Stevens M.D.
Principal Investigator
Norton Cancer Institute
Sponsor: Trillium Therapeutics Inc.

Leukemia

Extended treatment protocol for subjects continuing to benefit from Ibrutinib after completion of Ibrutinib (PCI-32965) clinical trials.
Study Type: Drug Study
Don Stevens  M.D.
Don Stevens M.D.
Principal Investigator
Norton Cancer Institute
Sponsor: Pharmacyclics, LLC

Leukemia

Tagraxofusp (SL-401) in Patients with Chronic Myelomonocytic Leukemia (CMML) or Myelofibrosis (MF)
Study Type: Drug Study
Don Stevens  M.D.
Don Stevens M.D.
Principal Investigator
Norton Cancer Institute
Sponsor: Stemline Therapeutics, Inc

Leukemia

An Open-label, Multicenter, Phase 1b Study of JNJ-74494550 (Cusatuzumab; Anti-CD70 Monoclonal Antibody) in Combination with Background Therapy for the Treatment of Subjects with Acute Myeloid Leukemia
Study Type: Drug Study
Don Stevens  M.D.
Don Stevens M.D.
Principal Investigator
Norton Cancer Institute
Sponsor: Janssen Research & Development

Leukemia

A Phase 1 Study of Safety, Pharmacokinetics, and Preliminary Activity of TAS1440, as a Single Agent and in Combination with All-Trans Retinoic Acid (ATRA) in Subjects with Relapsed or Refractory (r/r) Acute Myeloid Leukemia (AML)
Study Type: Drug Study
Joseph Maly  M.D.
Joseph Maly M.D.
Principal Investigator
Norton Cancer Institute
Sponsor: Astex Pharmaceuticals

Leukemia

A Phase 1 Study of Safety, Pharmacokinetics and Preliminary Activity of TAS1553 in Subjects with Relapsed or Refractory (R/R) Acute Myeloid Leukemia (AML) and Other Myeloid Neoplasms
Study Type: Drug Study
Joseph Maly  M.D.
Joseph Maly M.D.
Principal Investigator
Norton Cancer Institute
Sponsor: Astex Pharmaceuticals

Leukemia

A Phase I/II open label study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics and preliminary clinical efficacy of ONO-7475 in patients with acute leukemias or myelodysplastic syndromes
Study Type: Drug Study
Joseph Maly  M.D.
Joseph Maly M.D.
Principal Investigator
Norton Cancer Institute
Sponsor: ONO Pharmaceutical Co., Ltd.

Leukemia

A Phase 3 Open-Label, Randomized Study of LOXO-305 versus Investigator’s Choice of Idelalisib plus Rituximab or Bendamustine plus Rituximab in BTK Inhibitor Pretreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (BRUIN CLL-321)
Study Type: Drug Study
Joseph Maly  M.D.
Joseph Maly M.D.
Principal Investigator
Norton Cancer Institute
Sponsor: Loxo Oncology

Leukemia

A Phase 1b Dose Escalation Study of Lemzoparlimab in Combination with Azacitidine and/or Venetoclax in Subjects with Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS)
Study Type: Drug Study
Don Stevens  M.D.
Don Stevens M.D.
Principal Investigator
Norton Cancer Institute
Sponsor: AbbVie

Myeloid Leukemia

A Phase 1 Study of SEA-CD70 in Myeloid Malignancies
Study Type: Drug Study
Don Stevens  M.D.
Don Stevens M.D.
Principal Investigator
Norton Cancer Institute
Sponsor: Seattle Genetics, Inc

Relapsed or Refractory Lymphomas

A Phase 1, Multicenter, Open-Label, Dose-Escalation and Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of Intravenously Administered KT-333 in Adult Patients with Relapsed or Refractory Lymphomas, Large Granular Lymphocytic Leukemia and Solid Tumors
Study Type: Drug Study
Don Stevens  M.D.
Don Stevens M.D.
Principal Investigator
Norton Cancer Institute
Sponsor: Kymera Therapeutics, Inc
Cancer – 4673

Appointments

Cancer care that isn’t too far from home.

(502) 629-HOPE (4673)


Request an Appointment Online

Clinical trials

Clinical Trials

Learn more about clinical trials at Norton Healthcare
(502) 629-3500

CAR-T cell therapy triggers the body’s own defenses to fight cancer

CAR-T cell therapy takes advantage of the body’s immune system to fight off cancer, much like it does already to kick the common cold and other types of illness. Our bodies don’t always fight off […]

Read Full Story

UVB light as a treatment for cutaneous lymphoma

Ultraviolet light, specifically, narrowband UVB light, can reduce skin inflammation, especially as a treatment for eczema and psoriasis. A Louisville-area dermatologist is using this therapy as a treatment for cutaneous T-cell lymphoma, a blood cell […]

Read Full Story

In sickness and in health

The lump on Lonnie Gardner’s left arm looked innocuous. Maybe an insect bite, he reasoned. For weeks in 2014, the human resources professional went about his business, unconcerned. But the lump got larger and caught […]

Read Full Story

Cutaneous lymphoma: Blood cancer that starts in the skin

Why does a blood cancer start in the skin? Lymphomas are cancers of the immune system, which generally arise in lymph nodes and other lymphatic tissue.  The immune system consists of white blood cells, the […]

Read Full Story

Cancer-free patient finds hope from clinical trial

When Brenda Montgomery enrolled in a clinical trial at Norton Cancer Institute in February 2016, she hoped the new drug being researched would trounce the cancer she had battled for nine years. She also hoped […]

Read Full Story
Related Stories

CAR-T cell therapy triggers the body’s own defenses to fight cancer

CAR-T cell therapy takes advantage of the body’s immune system to fight off cancer, much like it does already to kick the common cold and other types of illness. Our bodies don’t always fight off […]

Read Full Story

UVB light as a treatment for cutaneous lymphoma

Ultraviolet light, specifically, narrowband UVB light, can reduce skin inflammation, especially as a treatment for eczema and psoriasis. A Louisville-area dermatologist is using this therapy as a treatment for cutaneous T-cell lymphoma, a blood cell […]

Read Full Story

In sickness and in health

The lump on Lonnie Gardner’s left arm looked innocuous. Maybe an insect bite, he reasoned. For weeks in 2014, the human resources professional went about his business, unconcerned. But the lump got larger and caught […]

Read Full Story

Cutaneous lymphoma: Blood cancer that starts in the skin

Why does a blood cancer start in the skin? Lymphomas are cancers of the immune system, which generally arise in lymph nodes and other lymphatic tissue.  The immune system consists of white blood cells, the […]

Read Full Story

Cancer-free patient finds hope from clinical trial

When Brenda Montgomery enrolled in a clinical trial at Norton Cancer Institute in February 2016, she hoped the new drug being researched would trounce the cancer she had battled for nine years. She also hoped […]

Read Full Story

Search our entire site.

Schedule an Appointment

Select an appointment date and time from available spots listed below.